BARINTHUS BIOTHERAPEUT

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

09 11 2023 13:24:43 提供 Nasdaq GlobeNewswire

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

09 11 2023 13:01:00 提供 Nasdaq GlobeNewswire

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

06 11 2023 06:05:56 提供 Nasdaq GlobeNewswire

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

13 9 2023 05:00:00 提供 Nasdaq GlobeNewswire

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

10 8 2023 05:00:01 提供 Nasdaq GlobeNewswire

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

21 6 2023 06:03:54 提供 Nasdaq GlobeNewswire

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

12 6 2023 04:30:00 提供 Nasdaq GlobeNewswire

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

12 5 2023 05:00:57 提供 Nasdaq GlobeNewswire

Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

17 4 2023 06:00:00 提供 Nasdaq GlobeNewswire

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

28 3 2023 05:00:11 提供 Nasdaq GlobeNewswire

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

24 3 2023 05:06:29 提供 Nasdaq GlobeNewswire

Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions

20 3 2023 05:00:00 提供 Nasdaq GlobeNewswire

Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer

30 1 2023 05:00:01 提供 Nasdaq GlobeNewswire

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

21 11 2022 07:31:34 提供 Nasdaq GlobeNewswire

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

10 11 2022 13:30:00 提供 Nasdaq GlobeNewswire

Vaccitech to Present at Upcoming November Investors Conferences

09 11 2022 05:00:01 提供 Nasdaq GlobeNewswire

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

07 11 2022 05:00:02 提供 Nasdaq GlobeNewswire

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

02 11 2022 05:00:02 提供 Nasdaq GlobeNewswire

Vaccitech Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 immunotherapeutic candidate for Chronic HBV Patients

31 10 2022 05:00:02 提供 Nasdaq GlobeNewswire

Publication in Cell Shows That Vaccitech’s SNAPvax™ Has the Potential to Treat Cancer by Reversing Suppressive Tumor Microenvironment with Novel “Vax-Innate” Paradigm

27 10 2022 04:00:01 提供 Nasdaq GlobeNewswire